Can This 1 Element Keep Vaxart in the Coronavirus Vaccine Race?

Vaxart's (NASDAQ: VXRT) shares plunged 58% in one trading session after one point in a clinical trial of its coronavirus vaccine candidate disappointed investors. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss the negatives and positives of the trial report -- and what they mean for the future of Vaxart's coronavirus vaccine program.